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Abstract
Background: The real-world incidence of chronic liver damage after transarterial chemoembolization (TACE) is
unclear. LiverT, a retrospective, observational study, assessed liver function deterioration after a single TACE in
real-world hepatocellular carcinoma (HCC) patients in US practice.
Methods: Eligible HCC patients identified from Optum’s integrated database using standard codes as having had
an index TACE between 2010 and 2016 with no additional oncologic therapy in the subsequent 3 months. At least
one laboratory value (bilirubin, albumin, aspartate transaminase [AST], alanine transaminase [ALT], international
normalized ratio [INR]) was required at baseline and the acute (≤29 days after TACE) and chronic (30–90 days after
TACE) periods. Due to lack of universally accepted liver function deterioration criteria, clinically meaningful changes
in laboratory parameters were pre-defined by authors (FP, RM, and SO).
Results: Of the 3963 TACE patients, 572 were eligible for analyses. Deterioration of liver function from baseline
occurred in the acute period and persisted in the chronic period (bilirubin 30 and 23%, albumin 52 and 31%, AST
44 and 25%, ALT 43 and 25%, INR 25 and 15%, respectively). In a subgroup analysis, a higher proportion of patients
with diabetes had deterioration in AST and ALT.
Conclusions: A clinically meaningful proportion of real-world HCC patients had deterioration of liver function-related
laboratory values 30–90 days after a single TACE in modern US practice. Future electronic health record research may
help determine causality. The present findings highlight the need for the careful selection of patients for TACE, which is
important to help optimize the benefit of the overall HCC treatment course.
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Background
Transarterial chemoembolization (TACE) is a commonly
used locoregional procedure that is recommended by sev-
eral guidelines as a first-line treatment for patients with
unresectable hepatocellular carcinoma (HCC) that is con-
fined to the liver with no vascular invasion [1–3].
Signs of acute liver injury, such as elevation in liver en-
zymes and worsening of liver function tests, are com-
monly seen following TACE [4–7]. Although this acute
deterioration (often defined as ≤30 days) is well docu-
mented, the extent to which TACE impacts mid- to long-
term liver function is less clear for real-world patients;
some studies have reported that acute liver damage may
become chronic or irreversible [7–9].
Liver damage associated with locoregional therapies may
adversely impact liver function, worsen prognosis, and
limit the use of effective systemic treatment options, which
have expanded over recent years [10, 11]. Due to the prom-
inent role of TACE for HCC treatment, establishing longer
term effects on liver function is important. This retrospect-
ive study aimed to assess the proportion of real-world
HCC patients in the US who develop chronic deterioration
of liver function after receiving a single TACE.
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Methods
Study design and patients
LiverT, a retrospective, observational, real-world cohort
study, used data from the Optum integrated database to
identify eligible US patients with HCC. Consequently, all
decisions of diagnostic procedures, treatment, disease
management, and resource utilization were dependent
on a mutual agreement between patient and physician,
without interference by the study sponsor or protocol.
Data collected by Optum from January 1, 2009 to June
30, 2016 were extracted. Optum, a division of United-
Health Group (Minnetonka, MN), comprises a number
of health data and information companies, providing an
integrated database of healthcare claims data, combined
with a longitudinal electronic health record database
housed by Humedica. The study population included pa-
tients ≥18 years of age who previously had at least one
TACE procedure and an HCC diagnosis code within 1
year prior to the index TACE (the first TACE procedure
performed January 1, 2010 to March 31, 2016). The time
periods were chosen to allow for at least 3 months’ fol-
low-up after TACE.
The cohort only included patients with at least one doc-
umented liver-related laboratory parameter (Table 1) at
each of the three time points: baseline (< 30 days before
TACE), acute (0–29 days after TACE), and chronic periods
(30–90 days after TACE). Patients were excluded if they
had received TACE within 1 year prior to the index TACE
and if they received any of these HCC treatments within
3months after the index TACE: additional TACE, radio-
frequency ablation, percutaneous ethanol injection, liver
resection or transplantation, chemotherapy, sorafenib, or
radioembolization by yttrium-90 (Y90). Patients were also
excluded if Y90 radioembolization was recorded on the
index date.
The procedural coding used for all criteria are listed in
Additional file 1: Table S1. Medical history (hepatitis B
virus [HBV], hepatitis C virus [HCV], alcoholic cirrhosis,
hypertension, and diabetes), disease status (portal vein
thrombosis [PVT], distant metastases, presence of asci-
tes, and encephalopathy), and prior HCC treatment were
also extracted. The two types of PVT, bland and portal
tumor infiltrated, could not be separately identified by
different codes. Data on medical history and prior HCC
treatment were available within 1 year prior to the index
TACE; data on disease status were available within 30
days of the index TACE. The database included the
month and date of death (when known).
Patient data were de-identified by an independent stat-
istical expert following the Health Insurance Portability
and Accountability Act of 1996 procedures and managed
according to customer data use agreements.
Outcomes and assessments
Outcomes
The primary endpoint was the proportion of patients
treated with TACE who had clinically relevant deterior-
ation of liver function laboratory values in the chronic
period compared with baseline (Table 1).
Secondary endpoints included the proportion of pa-
tients with liver deterioration during the acute period,
and liver deterioration in the acute and chronic periods
according to baseline albumin–bilirubin (ALBI) grade
(developed to objectively assess hepatic dysfunction), in the
absence of Child–Pugh scores [12]. ALBI grades were
determined by the ALBI score (log10 (bilirubin [μmL/L]) ×
0.66) + (albumin [g/L] × (− 0.085)) and defined as
grade 1 (≤ − 2.60), grade 2 (> − 2.60 to ≤ − 1.39), and
grade 3 (> − 1.39). Survival status was reported, defined as
the time from TACE to death from any cause. Patients
alive at the last date known were censored at that date.
Assessments
Levels of serum total bilirubin, albumin, aspartate trans-
aminase (AST), serum alanine transaminase (ALT), and
international normalized ratio (INR) were extracted from
the database. Due to lack of formally accepted criteria to
measure liver deterioration in the setting of HCC treat-
ment and limitations of currently used approaches, clinic-
ally relevant changes were pre-defined by preliminary
consensus of the authors (FP, RM, and SO only) (Table 1).
Simply reporting the mean worsening of the laboratory
values was not felt to sufficiently describe the clinical rele-
vance of worsening. The authors based their judgement of
deterioration upon the worsening of laboratory values in-
cluded in the Child–Pugh score and MELD score, the two
most widely utilized scores to assess liver function. Not-
ably, it was decided not to calculate the complete Child–
Pugh score since it would be subject to a high degree of
uncertainty, especially related to the lack of reported data
in the assessment for the presence and severity of ascites
and encephalopathy. The laboratory value closest to the
index date was used for the baseline period and the worst
laboratory value used for the acute period (assessed as
change from baseline). To minimize the risk of overesti-
mating long-term liver function deterioration following
Table 1 Liver function thresholds to establish clinically meaningful
deterioration after TACE in a real-world setting (primary analysis)
Parameter Deterioration threshold (change from baseline)
Serum total bilirubin Increase of ≥ 50%
Serum albumin Decrease by ≥ 0.3 g/dL
AST Increase of > 25%
ALT Increase of > 25%
INR Increase of ≥ 25%
ALT alanine transaminase, AST aspartate transaminase, INR international
normalized ratio, TACE transarterial chemoembolization
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TACE, the last (not worst) laboratory value was used for
the chronic period (compared with values from baseline
and the acute period). Conversely, the worst values were
selected in the acute period in order to capture the pos-
sibly largest, although transient impact that TACE had on
liver function. The median number of days related to the
last and worst values for the chronic period was assessed
for each parameter and are given in Additional file 1:
Table S2.
Sensitivity analysis
We performed a sensitivity analysis for bilirubin and al-
bumin based on Child–Pugh categorization because of
its prognostic importance in patients with cirrhosis
(Table 2). Child–Pugh considers the potential impact of
baseline levels and corresponds to the Common Ter-
minology Criteria for Adverse Events (CTCAE) deterior-
ation definitions.
Exploratory analyses
Exploratory subgroup analyses of liver function deterior-
ation were performed according to baseline Child–Pugh-
based bilirubin levels (< 2, 2–3, and > 3mg/dL for bilirubin
only), etiology (HBV, HCV, and alcoholic cirrhosis), dia-
betes status, and in patients without PVT at baseline. INR
was not evaluated here since anticoagulation use can po-
tentially confound the results. An additional exploratory
analysis was conducted to assess INR deterioration using
only the patients who did not use anticoagulants.
Statistical analysis
All variables were analyzed using descriptive statistics.
Laboratory results were described in absolute values
(mean and standard deviation, and median with range).
The Sign Test was used to generate P-values testing the
null hypothesis that the median difference in laboratory
values between two time points (from baseline to the
acute or chronic periods) is zero. Reported P-values
should be interpreted with caution and no adjustments for
multiplicity were made. The incidence of deterioration for
each laboratory value from baseline to the chronic and
acute periods was calculated based on the total population
and reported with a 95% confidence interval (CI).
Results
Baseline characteristics
A total of 3963 patients received at least one TACE
between January 1, 2010 and March 31, 2016 and
were ≥ 18 years of age with an HCC diagnosis code within
1 year prior to index TACE. The full study eligibility
criteria were met by 572 patients (14%); exclusions were
primarily due to lack of required laboratory data
(Additional file 1: Table S3). Most patients were male
(72%) and the median age was 62 years (Table 3).
Table 2 Bilirubin and albumin deterioration thresholds based
on Child–Pugh categorization (sensitivity analysis)
Parameter Deterioration thresholds
Serum total bilirubin at baseline
< 2mg/dL If ≥ 2 mg/dL or an increase of 100%
≤ 2–≤ 3 mg/dL If > 3 mg/dL
> 3mg/dL If increased by ≥ 1 mg/dL
Serum albumin level at baseline
> 3.5 g/dL If ≤ 3.5 g/dL or a decrease of ≥ 0.3 g/dL
≤ 2.8–≤ 3.5 g/dL If < 2.8 g/dL
< 2.8 g/dL If decreased by ≥ 0.3 g/dL
Table 3 Patient demographics and baseline characteristics prior
to TACE
TACE patients
(N = 572)
Median age, years (range) 62 (20–88)
Sex, n (%)
Male 411 (72)
Female 161 (28)
Disease characteristics, n (%)a
Ascites 94 (16)
Distant metastases 36 (6)
Portal vein thrombosis 29 (5)
Encephalopathy 4 (1)
General medical history, n (%)b
Hypertension 294 (51)
Diabetes 195 (34)
Potential etiology of HCC, n (%)b
Alcoholic cirrhosis 123 (22)
Non-alcoholic cirrhosis 425 (74)
HCV 217 (38)
HBV 39 (7)
Viral hepatitis, unspecified 17 (3)
Prior (non-TACE) treatment of HCC, n (%)b
Chemotherapy 45 (8)
Sorafenib 23 (4)
Liver resection 8 (1)
Percutaneous ethanol injection 3 (1)
Radioembolization by Y90 3 (1)
Liver transplantation 0
Radiofrequency ablation 0
aDiagnosis code < 30 days before index TACE, multiple diagnoses possible;
b< 1 year prior to index TACE, multiple responses possible
HBV hepatitis B virus, HCC hepatocellular carcinoma, HCV hepatitis C virus,
TACE transarterial chemoembolization, Y90 yttrium-90
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Liver function at baseline and after TACE
Laboratory values were available at all three time points
for most patients, apart from INR, which was available
for fewer patients. There was a large variation in base-
line levels, ranging from normal to outside of normal
ranges. In the acute period, deterioration is evident for
all laboratory parameters (Table 4). Importantly, levels of
AST and ALT were almost completely restored to base-
line values in the chronic period, which was expected
after an acute insult to the liver, such as with TACE. In
contrast, albumin, INR, and bilirubin were only partially
improved, remaining significantly worse compared with
baseline (Table 4).
In the primary analysis, although the proportion of pa-
tients with deterioration was greatest in the acute period,
some still had deterioration of liver-related parameters
in the chronic period (Fig. 1). This was in line with the
statistically significant impact of TACE on median la-
boratory values (Table 4). Deterioration of bilirubin in
the acute and chronic periods was observed for 30 and
23% of patients, respectively, and 52 and 31% for albu-
min. The sensitivity analysis using Child–Pugh-based de-
terioration thresholds produced similar results: bilirubin
deterioration was observed in 23% of patients (n = 104;
95% CI 19–26) and albumin deterioration in 30% of pa-
tients (n = 134; 95% CI 26–35) in the chronic period.
When stratified by baseline Child–Pugh bilirubin, the
proportion of patients with acute and chronic bilirubin
deterioration varied following TACE (Fig. 2). For lower
and upper bilirubin Child–Pugh categories, the propor-
tion of patients with deterioration was lower in the
chronic versus the acute period. However, with mild bili-
rubin elevation (2–3 mg/dL) bilirubin deterioration was
higher in the chronic versus the acute period.
When stratified by baseline ALBI grade, there was no
consistent trend in acute or chronic deterioration across
liver function laboratory parameters, except for albumin.
These data are shown in Additional file 1: Table S4. The
proportion of patients with albumin deterioration (de-
crease of ≥ 0.3 g/dL) in the acute and chronic periods
decreased as baseline ALBI grade increased.
Except for total bilirubin, a similar pattern of acute
and chronic deterioration was seen according to HCC
etiology (HBV, HCV, and alcoholic cirrhosis), the ab-
sence of PVT, and diabetes status. These analyses are
given in Additional file 1: Table S5 and S6. In the
chronic period, the proportion of patients with total bili-
rubin deterioration was lowest for patients with HBV
(12%) compared with alcoholic cirrhosis (25%) and HCV
(28%). The proportion of patients with INR deterioration
was higher in patients on anticoagulants compared with
those not on anticoagulants: 17 vs 36% and 9 vs 21% in
the acute and chronic periods, respectively. These results
are shown in Additional file 1: Table S7. The decrease in
the proportion of patients with INR deterioration be-
tween the acute and chronic periods were similar for
both groups.
CTCAE-based definitions of deterioration
For all parameters, an ad-hoc analysis assessed the pro-
portion of patients with deterioration according to Na-
tional Cancer Institute-CTCAE (v4.03) grade, which are
Table 4 Laboratory values at baseline and in the acute and chronic periods following TACE
Laboratory parameter Patient number,
n
Baseline
(value closest to index TACE)
Acute period
(highest value)
P-value acute
vs baseline
Chronic period
(latest value)
P-value chronic
vs baseline
Bilirubin, mg/dL 462
Mean (SD) 1.5 (1.1) 2.2 (2.9) – 2.3 (4.1) –
Median (range) 1.2 (0.09–6.9) 1.4 (0.3–37.9) P < .0001 1.2 (0.2–41.3) P = .008
Albumin, g/dL 442
Mean (SD) 3.2 (0.7) 2.9 (0.7) – 3.1 (0.7) –
Median (range) 3.3 (1.6–4.9) 2.8 (1.0–4.8) P < .0001 3.1 (1.4–4.8) P < .0001
AST, U/L 446
Mean (SD) 75.9 (61.5) 152.6 (270.4) 88.5 (187.3)
Median (range) 62 (11–844) 82 (13–3341) P < .0001 60 (9–3739) P = .600
ALT, U/L 441
Mean (SD) 59.5 (49.6) 122.1 (266.8) 62.1 (82.8)
Median (range) 45 (9–450) 60 (7–3198) P < .0001 42 (7–1122) P = .08
INR 251
Mean (SD) 1.3 (0.4) 1.6 (0.9) 1.5 (0.6)
Median (range) 1.2 (0.9–3.2) 1.3 (0.9–6.9) P < .0001 1.2 (0.9–6.9) P < .0001
Acute period, 0–29 days after TACE; chronic period, 30–90 days after TACE
ALT alanine transaminase, AST aspartate transaminase, INR international normalized ratio, SD standard deviation, TACE transarterial chemoembolization
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often used to report deterioration of liver-related param-
eters in clinical trials. In this analysis, the proportion of
patients with acute and chronic bilirubin deterioration
was 31 and 33%, respectively.
Patient survival after TACE
At 180 days following TACE, 88 patients had died: four
deaths were documented at day 30, 35 at day 90, and 49
at day 180 (Additional file 1: Table S8).
Discussion
The LiverT study demonstrated clinically meaningful
chronic, and acute, deterioration in liver function follow-
ing a single TACE in a US cohort of patients with HCC
treated in real-world practice. The consistency of this
deterioration, using pre-specified thresholds for liver
function laboratory parameters, suggests that a sizable
proportion of patients in real-world practice do not en-
tirely recover from liver damage after TACE [13].
The robustness of our findings was supported by an
additional analysis based on Child–Pugh bilirubin
thresholds, which showed a similar proportion of pa-
tients with acute and chronic bilirubin deterioration
compared with the primary analysis, except for a
baseline bilirubin of 2–3 mg/dL. For the group with this
relatively modest bilirubin elevation, the proportion of
patients with chronic deterioration was highest, suggest-
ing that liver function is relatively fragile in this patient
population. Exploratory analysis by baseline ALBI grade
also consistently showed deterioration of liver function
parameters (except albumin) in both periods, regardless
of initial ALBI score. Acute and chronic albumin deteri-
oration was lowest for patients with the worst baseline
ALBI scores (grade 3). This difference suggests that an
absolute decrease in albumin by ≥ 0.3 g/dL (pre-specified
threshold for deterioration) may be less likely to occur
when baseline albumin values are already low (i.e. pa-
tients with ALBI score > − 1.39; grade 3).
In an interim analysis of the prospective, observational
OPTIMIS study in non-US patients, deterioration of bili-
rubin and albumin following TACE was demonstrated in
14 and 25% of patients, respectively [14]. Although this is
lower than in LiverT, the patient population may have dif-
fered due to inclusion criteria, regional variation in HCC
risk factors, and differences in liver dysfunction reporting
[14]. Moreover, experience performing selective TACE
(associated with less liver adverse events compared to
lobar TACE) may be higher in centers selected for
Fig. 1 Proportion of patients with acute and chronic liver function deterioration after TACE compared to baseline (primary analysis).
Acute period, 0–29 days after TACE; chronic period, 30–90 days after TACE. Deterioration thresholds: bilirubin increase of ≥ 50%,
albumin decrease by 0.3 g/dL, AST increase of > 25%, ALT increase of > 25%, INR increase of ≥ 25%, all compared with baseline.
ALT alanine transaminase, AST aspartate transaminase, CI confidence interval, INR international normalized ratio, TACE transarterial chemoembolization
Fig. 2 Bilirubin deterioration in acute and chronic periods after TACE using baseline Child–Pugh bilirubin categories. Acute period, 0–29
days after TACE; chronic period, 30–90 days after TACE. Deterioration threshold: bilirubin increase of ≥ 50% compared with baseline.
TACE transarterial chemoembolization
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prospective studies compared with those in which our
real-world cohort were treated; however, in this study, it
was not possible to obtain data on TACE selectivity. Al-
though retrospective studies have also reported deterior-
ation in liver function after TACE [15–17], liver-related
abnormalities were not reported for acute versus chronic
time points after TACE. Thus, LiverT may provide further
insight into the time between TACE and occurrence of
liver function deterioration in real-world patients.
Several clinical trials have demonstrated liver function
deterioration after TACE; however, our real-world findings
may differ due to a more heterogeneous patient popula-
tion and more variable TACE experience [4, 18–21]. Both
factors may have contributed to the higher rate of death
in LiverT than generally reported in TACE clinical trials,
suggesting a considerable number of real-world TACE
treated HCC patients had worse outcomes.
In the phase 2, randomized, double-blind, placebo-con-
trolled SPACE trial, liver function deterioration following
TACE plus placebo was low; hyperbilirubinemia was only
reported in 9% of patients [19]. Unlike LiverT, SPACE only
included patients with measurable HCC lesions, no MVI
or distant metastases, and adequate liver function [19].
However, in our study, baseline values were highly variable
and, occasionally, would not have met clinical trial inclu-
sion criteria. Additionally, some patients had distant me-
tastases (6%) and PVT (5%) at baseline, both of which are
relative contraindications for TACE [22]. As a reflection
of real-world clinical practice of TACE, our results high-
light the need for appropriate and accurate patient selec-
tion to minimize the risk of chronic hepatic dysfunction
following TACE [23].
As with all observational, retrospective studies, a number
of limitations were unavoidable and should be outlined
and discussed. Limitations include potential sampling bias
and confounding. Here, we leveraged a national dataset
populated with International Classification of Disease
codes and structured laboratory data; however, data
source-related limitations include potential absences, mis-
classifications from coding errors, and lack of patient re-
cords from which relevant data can be abstracted, such as
physician-documented Child–Pugh score, and the size and
number of tumors. Missing additional data included la-
boratory values needed for the analysis of the primary end-
point, which could lead to an underestimation of liver
function deterioration. For example, a patient with a mild
elevation in AST may have had a severe increase in serum
bilirubin; however, if only AST was recorded in the data-
base, liver deterioration could have been underreported.
Important TACE procedural information was also unavail-
able, including the selectivity of the TACE procedure.
There is evidence that a more selective approach to deliv-
ering TACE (i.e. segmental) leads to less liver damage and
better outcomes [24], but data were insufficient to verify
whether greater chronic liver damage was associated with
non-selective procedures. At the time of analysis, a large,
longitudinal HCC database with structured and unstruc-
tured data was not readily available. However, 2010 was
selected as the starting year for the study because it was
assumed that enough time had passed from the demon-
stration of the superiority of selective TACE [24], and that
this procedure would have been adopted as standard
practice. Additionally, data were not available to stratify
patients according to the degree of tumor burden and
stage, similar to many other retrospective studies in this
field. Thus, our data source represented the best
compromise for evaluation of a relatively large cohort of
real-world HCC patients. Additionally, the study only
included patients who did not receive additional HCC
treatment within 3months after index TACE. While
absence of additional therapy minimized confounding, it
may have biased the cohort towards sicker patients by
excluding those without post-TACE liver dysfunction who
required subsequent treatment in the short term. This bias
towards sicker patients may explain the higher percentage
of liver function deterioration and mortality compared with
other clinical studies. In addition, excluding patients
because of a lack of laboratory data may also have contrib-
uted to selection bias because it could be implied that
patients included in the analysis were more closely
followed and monitored for clinical reasons, which could
impact liver function. In addition, patients who experi-
enced severe deterioration, leading to death before any
further chronic reassessment, would also not have been
included. A proportion of patients included in the analyses
were treated with TACE despite having distant metastases
(6%) and/or PVT (5%), both of which are contraindications
for TACE. Lastly, there were no control groups included in
the study, such as MELD-matched patients without HCC,
who could have demonstrated prevalence of liver function
deterioration over a 3-month period without the concomi-
tant effect of liver-directed therapy. Despite these limita-
tions, we believe our cohort is sufficiently representative of
real-life situations after TACE to provide insights on the
risk of acute and chronic liver dysfunction.
Conclusions
In summary, these results demonstrate the occurrence
of acute and chronic deterioration of liver function fol-
lowing a single TACE treatment in a modern cohort of
US HCC patients. The data also suggest that, for a pro-
portion of real-life patients, TACE can be associated
with chronic liver function deterioration. The use of a
range of different systemic therapies (targeted therapy,
anti-programmed cell death 1/ligand-1 treatment, and
others) after TACE is increasing following numerous
positive survival results in HCC patients with relatively
well-preserved liver function [23, 25]. Liver dysfunction
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may preclude such systemic therapy options. Therefore,
the present findings highlight the need for the careful se-
lection of patients for TACE to help optimize the benefit
of the overall HCC treatment course.
Additional file
Additional file 1: This file includes additional results such as figures and
tables. (DOCX 60 kb)
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